Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSPC Pharmaceutical Group ( (HK:1093) ) has issued an announcement.
CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group, reported its unaudited financial results for the first half of 2025, revealing a 7.99% increase in operating revenue compared to the same period last year. However, the company experienced a net loss attributable to shareholders, highlighting challenges in profitability despite increased revenue. The announcement underscores the importance for stakeholders to exercise caution when dealing in the company’s securities due to the unaudited nature of the financial information.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a prominent player in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of innovative pharmaceutical products. The company is listed on the Hong Kong Stock Exchange and has a significant market presence in China.
Average Trading Volume: 218,061,713
Technical Sentiment Signal: Buy
Current Market Cap: HK$120.2B
See more data about 1093 stock on TipRanks’ Stock Analysis page.